Search

Correction for "PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease," by Eva L. Morozko, Charlene Smith-Geater, Alejandro Mas Monteys, Subrata Pradhan, Ryan G. Lim, Peter Langfelder, Marketta Kachemov, Austin Hill, Jennifer T. Stocksdale, Pieter R. Cullis, Jie Wu, Joseph Ochaba, Ricardo Miramontes, Anirban Chakraborty, Tapas K. Hazra, Alice Lau, Sophie St-cyr, Iliana Orellana, Lexi Kopan, Keona Q. Wang, Sylvia Yeung, Blair R. Leavitt, Jack C. Reidling, X. William Yang, Joan S. Steffan, Beverly L. Davidson, Partha S. Sarkar, and Leslie M. Thompson, which published January 19, 2021; 10.1073/pnas.2021836118 (Proc. Natl. Acad. Sci. U.S.A. 118, e2021836118). The authors note that Jayesh A. Kulkarni and Josh Zaifman should be added to the author list between Marketta Kachemov and Austin Hill. Jayesh A. Kulkarni should be credited with Contributed new reagents/analytical tools and Performed Research. Josh Zaifman should be credited with Contributed new reagents/analytical tools and Performed Research. The corrected author line, affiliation line, and author contributions appear below. The online version has been corrected.

Background: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. Methods: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. Results: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P

Retinal gene therapy with adeno-associated viral (AAV) vectors is safe and effective in humans. However, the limited cargo capacity of AAV prevents their use for therapy of those inherited retinopathies (IRs) due to mutations in large (>5 kb) genes. Viral vectors derived from adenovirus (Ad), lentivirus (LV) and herpes virus (HV) can package large DNA sequences, but do not target efficiently retinal photoreceptors (PRs) where the majority of genes responsible for IRs are expressed. Here, we have evaluated the mouse retinal transduction profiles of vectors derived from 16 different Ad serotypes, 7 LV pseudotypes and from a bovine HV. Most of the vectors tested transduced efficiently the retinal pigment epithelium. We found that LV-GP64 tends to transduce more PRs than the canonical LV-VSVG, albeit this was restricted to a narrow region. We observed more extensive PR transduction with HdAd1, 2 and 5/F35++ than with LV, although none of them outperformed the canonical HdAd5 or matched the extension of PR transduction achieved with AAV2/8. © 2014 Macmillan Publishers Limited All rights reserved.